Abstract
Summary
Idiopathic pulmonary fibrosis is a condition in which the tissues in the lungs become thick and stiff over time. As a result of thickening of lung tissues, brain and other organs are unable receive optimum oxygen.
LPI (LP Information)' newest research report, the “Idiopathic Pulmonary Fibrosis Industry Forecast” looks at past sales and reviews total world Idiopathic Pulmonary Fibrosis sales in 2022, providing a comprehensive analysis by region and market sector of projected Idiopathic Pulmonary Fibrosis sales for 2023 through 2029. With Idiopathic Pulmonary Fibrosis sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Idiopathic Pulmonary Fibrosis industry.
This Insight Report provides a comprehensive analysis of the global Idiopathic Pulmonary Fibrosis landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Idiopathic Pulmonary Fibrosis portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Idiopathic Pulmonary Fibrosis market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Idiopathic Pulmonary Fibrosis and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Idiopathic Pulmonary Fibrosis.
The global Idiopathic Pulmonary Fibrosis market size is projected to grow from US$ 1694 million in 2022 to US$ 3270.8 million in 2029; it is expected to grow at a CAGR of 9.9% from 2023 to 2029.
An increase in the incidence and prevalence of fibrotic diseases is the primary driver for the growth of this market. Idiopathic pulmonary fibrosis most commonly affects middle-aged to older adults and is characterized by the scarring of lung tissues. In older people, these scars tend to build up and affect the normal functioning of lungs. Thus, an increase in aging population leads to increased prevalence of the disease, which in turn results in market growth during the predicted period.
This report presents a comprehensive overview, market shares, and growth opportunities of Idiopathic Pulmonary Fibrosis market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Systemic Corticosteroids
Immunosuppressant Drugs
Tyrosine Kinase Inhibitors
Antifibrotic Agents
Segmentation by application
Hospitals
Clinics
Ambulatory Surgical Centers
Academic and Research Organizations
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
MediciNova
Boehringer Ingelheim
F. Hoffmann-La Roche
FibroGen
Promedior
Merck
Galapagos
Prometic Life Sciences
Cipla
LPI (LP Information)' newest research report, the “Idiopathic Pulmonary Fibrosis Industry Forecast” looks at past sales and reviews total world Idiopathic Pulmonary Fibrosis sales in 2022, providing a comprehensive analysis by region and market sector of projected Idiopathic Pulmonary Fibrosis sales for 2023 through 2029. With Idiopathic Pulmonary Fibrosis sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Idiopathic Pulmonary Fibrosis industry.
This Insight Report provides a comprehensive analysis of the global Idiopathic Pulmonary Fibrosis landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Idiopathic Pulmonary Fibrosis portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Idiopathic Pulmonary Fibrosis market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Idiopathic Pulmonary Fibrosis and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Idiopathic Pulmonary Fibrosis.
The global Idiopathic Pulmonary Fibrosis market size is projected to grow from US$ 1694 million in 2022 to US$ 3270.8 million in 2029; it is expected to grow at a CAGR of 9.9% from 2023 to 2029.
An increase in the incidence and prevalence of fibrotic diseases is the primary driver for the growth of this market. Idiopathic pulmonary fibrosis most commonly affects middle-aged to older adults and is characterized by the scarring of lung tissues. In older people, these scars tend to build up and affect the normal functioning of lungs. Thus, an increase in aging population leads to increased prevalence of the disease, which in turn results in market growth during the predicted period.
This report presents a comprehensive overview, market shares, and growth opportunities of Idiopathic Pulmonary Fibrosis market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Systemic Corticosteroids
Immunosuppressant Drugs
Tyrosine Kinase Inhibitors
Antifibrotic Agents
Segmentation by application
Hospitals
Clinics
Ambulatory Surgical Centers
Academic and Research Organizations
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
MediciNova
Boehringer Ingelheim
F. Hoffmann-La Roche
FibroGen
Promedior
Merck
Galapagos
Prometic Life Sciences
Cipla
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Idiopathic Pulmonary Fibrosis Market Size 2018-2029
2.1.2 Idiopathic Pulmonary Fibrosis Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Idiopathic Pulmonary Fibrosis Segment by Type
2.2.1 Systemic Corticosteroids
2.2.2 Immunosuppressant Drugs
2.2.3 Tyrosine Kinase Inhibitors
2.2.4 Antifibrotic Agents
2.3 Idiopathic Pulmonary Fibrosis Market Size by Type
2.3.1 Idiopathic Pulmonary Fibrosis Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Idiopathic Pulmonary Fibrosis Market Size Market Share by Type (2018-2023)
2.4 Idiopathic Pulmonary Fibrosis Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Ambulatory Surgical Centers
2.4.4 Academic and Research Organizations
2.5 Idiopathic Pulmonary Fibrosis Market Size by Application
2.5.1 Idiopathic Pulmonary Fibrosis Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Idiopathic Pulmonary Fibrosis Market Size Market Share by Application (2018-2023)
3 Idiopathic Pulmonary Fibrosis Market Size by Player
3.1 Idiopathic Pulmonary Fibrosis Market Size Market Share by Players
3.1.1 Global Idiopathic Pulmonary Fibrosis Revenue by Players (2018-2023)
3.1.2 Global Idiopathic Pulmonary Fibrosis Revenue Market Share by Players (2018-2023)
3.2 Global Idiopathic Pulmonary Fibrosis Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Idiopathic Pulmonary Fibrosis by Regions
4.1 Idiopathic Pulmonary Fibrosis Market Size by Regions (2018-2023)
4.2 Americas Idiopathic Pulmonary Fibrosis Market Size Growth (2018-2023)
4.3 APAC Idiopathic Pulmonary Fibrosis Market Size Growth (2018-2023)
4.4 Europe Idiopathic Pulmonary Fibrosis Market Size Growth (2018-2023)
4.5 Middle East & Africa Idiopathic Pulmonary Fibrosis Market Size Growth (2018-2023)
5 Americas
5.1 Americas Idiopathic Pulmonary Fibrosis Market Size by Country (2018-2023)
5.2 Americas Idiopathic Pulmonary Fibrosis Market Size by Type (2018-2023)
5.3 Americas Idiopathic Pulmonary Fibrosis Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Idiopathic Pulmonary Fibrosis Market Size by Region (2018-2023)
6.2 APAC Idiopathic Pulmonary Fibrosis Market Size by Type (2018-2023)
6.3 APAC Idiopathic Pulmonary Fibrosis Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Idiopathic Pulmonary Fibrosis by Country (2018-2023)
7.2 Europe Idiopathic Pulmonary Fibrosis Market Size by Type (2018-2023)
7.3 Europe Idiopathic Pulmonary Fibrosis Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Idiopathic Pulmonary Fibrosis by Region (2018-2023)
8.2 Middle East & Africa Idiopathic Pulmonary Fibrosis Market Size by Type (2018-2023)
8.3 Middle East & Africa Idiopathic Pulmonary Fibrosis Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Idiopathic Pulmonary Fibrosis Market Forecast
10.1 Global Idiopathic Pulmonary Fibrosis Forecast by Regions (2024-2029)
10.1.1 Global Idiopathic Pulmonary Fibrosis Forecast by Regions (2024-2029)
10.1.2 Americas Idiopathic Pulmonary Fibrosis Forecast
10.1.3 APAC Idiopathic Pulmonary Fibrosis Forecast
10.1.4 Europe Idiopathic Pulmonary Fibrosis Forecast
10.1.5 Middle East & Africa Idiopathic Pulmonary Fibrosis Forecast
10.2 Americas Idiopathic Pulmonary Fibrosis Forecast by Country (2024-2029)
10.2.1 United States Idiopathic Pulmonary Fibrosis Market Forecast
10.2.2 Canada Idiopathic Pulmonary Fibrosis Market Forecast
10.2.3 Mexico Idiopathic Pulmonary Fibrosis Market Forecast
10.2.4 Brazil Idiopathic Pulmonary Fibrosis Market Forecast
10.3 APAC Idiopathic Pulmonary Fibrosis Forecast by Region (2024-2029)
10.3.1 China Idiopathic Pulmonary Fibrosis Market Forecast
10.3.2 Japan Idiopathic Pulmonary Fibrosis Market Forecast
10.3.3 Korea Idiopathic Pulmonary Fibrosis Market Forecast
10.3.4 Southeast Asia Idiopathic Pulmonary Fibrosis Market Forecast
10.3.5 India Idiopathic Pulmonary Fibrosis Market Forecast
10.3.6 Australia Idiopathic Pulmonary Fibrosis Market Forecast
10.4 Europe Idiopathic Pulmonary Fibrosis Forecast by Country (2024-2029)
10.4.1 Germany Idiopathic Pulmonary Fibrosis Market Forecast
10.4.2 France Idiopathic Pulmonary Fibrosis Market Forecast
10.4.3 UK Idiopathic Pulmonary Fibrosis Market Forecast
10.4.4 Italy Idiopathic Pulmonary Fibrosis Market Forecast
10.4.5 Russia Idiopathic Pulmonary Fibrosis Market Forecast
10.5 Middle East & Africa Idiopathic Pulmonary Fibrosis Forecast by Region (2024-2029)
10.5.1 Egypt Idiopathic Pulmonary Fibrosis Market Forecast
10.5.2 South Africa Idiopathic Pulmonary Fibrosis Market Forecast
10.5.3 Israel Idiopathic Pulmonary Fibrosis Market Forecast
10.5.4 Turkey Idiopathic Pulmonary Fibrosis Market Forecast
10.5.5 GCC Countries Idiopathic Pulmonary Fibrosis Market Forecast
10.6 Global Idiopathic Pulmonary Fibrosis Forecast by Type (2024-2029)
10.7 Global Idiopathic Pulmonary Fibrosis Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 MediciNova
11.1.1 MediciNova Company Information
11.1.2 MediciNova Idiopathic Pulmonary Fibrosis Product Offered
11.1.3 MediciNova Idiopathic Pulmonary Fibrosis Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 MediciNova Main Business Overview
11.1.5 MediciNova Latest Developments
11.2 Boehringer Ingelheim
11.2.1 Boehringer Ingelheim Company Information
11.2.2 Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Product Offered
11.2.3 Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Boehringer Ingelheim Main Business Overview
11.2.5 Boehringer Ingelheim Latest Developments
11.3 F. Hoffmann-La Roche
11.3.1 F. Hoffmann-La Roche Company Information
11.3.2 F. Hoffmann-La Roche Idiopathic Pulmonary Fibrosis Product Offered
11.3.3 F. Hoffmann-La Roche Idiopathic Pulmonary Fibrosis Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 F. Hoffmann-La Roche Main Business Overview
11.3.5 F. Hoffmann-La Roche Latest Developments
11.4 FibroGen
11.4.1 FibroGen Company Information
11.4.2 FibroGen Idiopathic Pulmonary Fibrosis Product Offered
11.4.3 FibroGen Idiopathic Pulmonary Fibrosis Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 FibroGen Main Business Overview
11.4.5 FibroGen Latest Developments
11.5 Promedior
11.5.1 Promedior Company Information
11.5.2 Promedior Idiopathic Pulmonary Fibrosis Product Offered
11.5.3 Promedior Idiopathic Pulmonary Fibrosis Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Promedior Main Business Overview
11.5.5 Promedior Latest Developments
11.6 Merck
11.6.1 Merck Company Information
11.6.2 Merck Idiopathic Pulmonary Fibrosis Product Offered
11.6.3 Merck Idiopathic Pulmonary Fibrosis Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Merck Main Business Overview
11.6.5 Merck Latest Developments
11.7 Galapagos
11.7.1 Galapagos Company Information
11.7.2 Galapagos Idiopathic Pulmonary Fibrosis Product Offered
11.7.3 Galapagos Idiopathic Pulmonary Fibrosis Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Galapagos Main Business Overview
11.7.5 Galapagos Latest Developments
11.8 Prometic Life Sciences
11.8.1 Prometic Life Sciences Company Information
11.8.2 Prometic Life Sciences Idiopathic Pulmonary Fibrosis Product Offered
11.8.3 Prometic Life Sciences Idiopathic Pulmonary Fibrosis Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Prometic Life Sciences Main Business Overview
11.8.5 Prometic Life Sciences Latest Developments
11.9 Cipla
11.9.1 Cipla Company Information
11.9.2 Cipla Idiopathic Pulmonary Fibrosis Product Offered
11.9.3 Cipla Idiopathic Pulmonary Fibrosis Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Cipla Main Business Overview
11.9.5 Cipla Latest Developments
12 Research Findings and Conclusion